DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4% – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT) shot up 8.4% on Monday . The stock traded as high as $14.49 and last traded at $14.61. Approximately 374,754 shares traded hands during mid-day trading, an increase of 22% from the average session volume of 307,907 shares. The stock had previously closed at $13.48.

Analyst Ratings Changes

Several equities analysts have recently issued reports on DBVT shares. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Guggenheim restated a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a report on Monday, May 4th. Finally, Citizens Jmp raised their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Stock Up 7.1%

The company has a market capitalization of $854.90 million, a P/E ratio of -4.16 and a beta of -0.93. The company has a 50-day moving average of $15.58 and a two-hundred day moving average of $19.00.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. As a group, equities analysts expect that DBV Technologies S.A. will post -2.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. MPM Bioimpact LLC bought a new position in shares of DBV Technologies in the 2nd quarter worth about $9,649,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the second quarter worth about $9,659,000. Octagon Capital Advisors LP bought a new position in shares of DBV Technologies during the second quarter valued at approximately $9,315,000. Two Sigma Investments LP bought a new position in shares of DBV Technologies during the third quarter valued at approximately $167,000. Finally, Citadel Advisors LLC purchased a new position in shares of DBV Technologies during the third quarter valued at approximately $220,000. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.